151 related articles for article (PubMed ID: 19893928)
1. Report on hearing loss in oncology.
Schultz C; Goffi-Gomez MV; Liberman PH; Carvalho AL
Braz J Otorhinolaryngol; 2009; 75(5):634-41. PubMed ID: 19893928
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin ototoxicity: the importance of baseline audiometry.
Nagy JL; Adelstein DJ; Newman CW; Rybicki LA; Rice TW; Lavertu P
Am J Clin Oncol; 1999 Jun; 22(3):305-8. PubMed ID: 10362343
[TBL] [Abstract][Full Text] [Related]
3. Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma.
Bass JK; Huang J; Onar-Thomas A; Chang KW; Bhagat SP; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Heath JA; McCowage G; Cohn RJ; Fisher MJ; Robinson G; Broniscer A; Gajjar A; Gurney JG
Pediatr Blood Cancer; 2014 Apr; 61(4):601-5. PubMed ID: 24504791
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
5. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
7. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria.
Waissbluth S; Peleva E; Daniel SJ
Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1187-1196. PubMed ID: 27245751
[TBL] [Abstract][Full Text] [Related]
8. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
10. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
11. Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
Riedemann L; Lanvers C; Deuster D; Peters U; Boos J; Jürgens H; am Zehnhoff-Dinnesen A
Pharmacogenomics J; 2008 Feb; 8(1):23-8. PubMed ID: 17457342
[TBL] [Abstract][Full Text] [Related]
12. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM; Bartholomäus E; Deuster D; Heinecke A; Dinnesen AG
HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215
[TBL] [Abstract][Full Text] [Related]
13. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
14. ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin.
De Lauretis A; De Capua B; Barbieri MT; Bellussi L; Passàli D
Scand Audiol; 1999; 28(3):139-43. PubMed ID: 10489862
[TBL] [Abstract][Full Text] [Related]
15. Patterns of hearing loss resulting from cis-platinum therapy.
Blakley BW; Myers SF
Otolaryngol Head Neck Surg; 1993 Sep; 109(3 Pt 1):385-91. PubMed ID: 8414553
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
[TBL] [Abstract][Full Text] [Related]
18. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
van der Hulst RJ; Dreschler WA; Urbanus NA
Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541
[TBL] [Abstract][Full Text] [Related]
19. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin ototoxicity.
Malhotra H
Indian J Cancer; 2009; 46(4):262-3. PubMed ID: 19749455
[No Abstract] [Full Text] [Related]
[Next] [New Search]
